Yungjin Pharm. Co., Ltd. (KRX:003520)

Revenue by Product

Financials in millions KRW. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005	Dec 31, 1998	Dec 31, 1997
Antibiotics	51.95B
Antibiotics Growth	12.52%
Intravenous and Enteral Nutrition	44.35B
Intravenous and Enteral Nutrition Growth	5.31%
Circulatory System	29.61B
Circulatory System Growth	4.52%
Finished Products and Raw Materials	27.59B
Finished Products and Raw Materials Growth	14.38%
Neuropsychiatric System	23.29B
Neuropsychiatric System Growth	11.54%
Antipyretic, Analgesic and Anti-inflammatory	16.46B
Antipyretic, Analgesic and Anti-inflammatory Growth	-13.58%
Respiratory System	13.76B
Respiratory System Growth	8.26%
Digestive System	12.58B
Digestive System Growth	14.49%
Processed Goods	4.53B
Processed Goods Growth	18.63%
Other	27.94B
Other Growth	4.48%
Other	27.94B
Other Growth	4.48%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005	Dec 31, 1998	Dec 31, 1997
Other	2.34B
Other Growth	126.11%
South Korea	224.46B
South Korea Growth	6.49%
Japan	23.95B
Japan Growth	23.53%
Taiwan	1.29B
Taiwan Growth	-64.98%
Other	2.34B
Other Growth	126.11%